HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
trastuzumab + lapatinib Sensitive: A1 - Approval
|
HR negative
|
Hormone Receptor Negative Breast Cancer
|
HR negative
|
Hormone Receptor Negative Breast Cancer
|
TCHP Sensitive: C3 – Early Trials
|
TCHP Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Negative Breast Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification + HER-2 R157W
|
Hormone Receptor Negative Breast Cancer
|
HER-2 amplification + HER-2 R157W
|
Hormone Receptor Negative Breast Cancer
|
pyrotinib Sensitive: C4 – Case Studies
|
pyrotinib Sensitive: C4 – Case Studies
|